Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer

Takuji Okusaka, Junji Furuse, Akihiro Funakoshi, Tatsuya Ioka, Kenji Yamao, Shinichi Ohkawa, Narikazu Boku, Yoshito Komatsu, Shoji Nakamori, Haruo Iguchi, Tetsuhide Ito, Kazuhiko Nakagawa, Kohei Nakachi

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Fingerprint Dive into the research topics of 'Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences